TY - JOUR
T1 - Prediagnostic nonsteroidal anti-inflammatory drug use and lung cancer survival in the VITAL study
AU - Brasky, Theodore M.
AU - Baik, Christina S.
AU - Slatore, Christopher G.
AU - Alvarado, Mariela
AU - White, Emily
N1 - Funding Information:
This work was supported by National Institutes of Health grants R25-CA094880 (National Cancer Institute) and K05-CA154337 (National Cancer Institute and Office of Dietary Supplements). Dr. Slatore is a recipient of a VA HSRD Career Development Award and is supported by resources from the Portland VA Medical Center. The Department of Veterans Affairs did not have a role in the conduct of the study, in the collection, management, analysis, or interpretation of data, or in the preparation of the article. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs or the US Government.
PY - 2012/10
Y1 - 2012/10
N2 - Introduction: Inflammation is important for lung oncogenesis. Use of nonsteroidal anti-inflammatory drugs (NSAIDs) has been shown to improve colorectal cancer survival. However, few studies have examined the association in lung cancer patients. Methods: The VITamins And Lifestyle (VITAL) cohort includes Washington State residents, aged 50 to 76 years, who completed a baseline questionnaire between 2000 and 2002. Participants responded on the frequency and duration of use of individual NSAIDs in the previous 10 years. Subjects of this study were 785 members of the cohort, who were identified with incident lung cancer from baseline through 2007 through linkage to a population-based cancer registry. Participants were followed for lung cancer death through linkage to state records of death through 2009. Adjusted proportional hazards models estimated hazard ratios (HR) and 95% confidence intervals (CI) for the association between NSAIDs and lung cancer death. Results: Five hundred and twenty-two participants (66%) died from lung cancer. Relative to nonuse, high (≥4 days/week and ≥4 years) prediagnostic use of regular-strength or low-dose aspirin (HR 0.99, 95% CI: 0.74-1.33 and HR 0.89, 95% CI: 0.67-1.17, respectively) or total nonaspirin NSAIDs (HR 1.20, 95% CI: 0.79-1.83) did not reduce lung cancer death. However, high use of ibuprofen was associated with a 62% increased risk of lung cancer death (HR 1.62, 95% CI: 1.01-2.58). Conclusions: Long-term, prediagnostic NSAID use does not improve lung cancer survival overall. Use of ibuprofen may reduce survival from lung cancer. Our results underscore the need for further study of the mechanisms of action for individual NSAIDs with regard to cancer survival.
AB - Introduction: Inflammation is important for lung oncogenesis. Use of nonsteroidal anti-inflammatory drugs (NSAIDs) has been shown to improve colorectal cancer survival. However, few studies have examined the association in lung cancer patients. Methods: The VITamins And Lifestyle (VITAL) cohort includes Washington State residents, aged 50 to 76 years, who completed a baseline questionnaire between 2000 and 2002. Participants responded on the frequency and duration of use of individual NSAIDs in the previous 10 years. Subjects of this study were 785 members of the cohort, who were identified with incident lung cancer from baseline through 2007 through linkage to a population-based cancer registry. Participants were followed for lung cancer death through linkage to state records of death through 2009. Adjusted proportional hazards models estimated hazard ratios (HR) and 95% confidence intervals (CI) for the association between NSAIDs and lung cancer death. Results: Five hundred and twenty-two participants (66%) died from lung cancer. Relative to nonuse, high (≥4 days/week and ≥4 years) prediagnostic use of regular-strength or low-dose aspirin (HR 0.99, 95% CI: 0.74-1.33 and HR 0.89, 95% CI: 0.67-1.17, respectively) or total nonaspirin NSAIDs (HR 1.20, 95% CI: 0.79-1.83) did not reduce lung cancer death. However, high use of ibuprofen was associated with a 62% increased risk of lung cancer death (HR 1.62, 95% CI: 1.01-2.58). Conclusions: Long-term, prediagnostic NSAID use does not improve lung cancer survival overall. Use of ibuprofen may reduce survival from lung cancer. Our results underscore the need for further study of the mechanisms of action for individual NSAIDs with regard to cancer survival.
UR - http://www.scopus.com/inward/record.url?scp=84866627026&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84866627026&partnerID=8YFLogxK
U2 - 10.1097/JTO.0b013e3182641bdc
DO - 10.1097/JTO.0b013e3182641bdc
M3 - Article
C2 - 22982651
AN - SCOPUS:84866627026
SN - 1556-0864
VL - 7
SP - 1503
EP - 1512
JO - Journal of Thoracic Oncology
JF - Journal of Thoracic Oncology
IS - 10
ER -